Adocia : € 36m of cash at end-June 2020
>Opex under control - Adocia yesterday evening reported its H1 2020 financial results, with sales of € 0.6m (vs € 1.7m in 2019) over the period, which reflect the payments for services provided and R&D delivered in the context of its partnership with Tonghua Dongbao for the development and marketing of BC Lispro and Combo in China. The loss was reduced to -€ 11.1m (vs -€ 13.4m in 2019), due to lower charges for legal proceedings against its former partner Eli Lilly an...ADOCIA is a biotechnology company based in France. Co. specializes in the development of formulations for already-approved therapeutic proteins with a primary focus on insulins and treatments for diabetic foot ulcers. Co.'s biotherapy products are used in tissue regeneration and for treating chronic diseases. Co.'s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins in areas such as wound Healing, diabetes, ulcers and monoclonal antibody creation. Co. also maintains activities in the formulation of monoclonal antibodies for the treatment of various chronic pathologies (oncology, inflammation, etc.).
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.